title: Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
abstract: The Soft Tissue and Bone Sarcoma Group of the European Organization on Research and Treatment of Cancer has conducted a number of studies of chemotherapy in advanced disease over the past 15 years. Following the discovery that the CYVADIC regimen (cyclophosphamide/vincristine/doxorubicin/dimethyl imidazole carboxamide) was less active than had been reported originally, the individual components of CYVADIC were studied. This showed that doxorubicin had considerable activity and that ifosfamide 5 g/m2 given over 24 hours was at least as active as cyclophosphamide. Subsequent studies have therefore centered on a combination of doxorubicin and ifosfamide. A large randomized trial showed no significant benefit of doxorubicin/ifosfamide over single-agent doxorubicin, but the doses of doxorubicin were different. More recently, using bone marrow growth factors, it has been possible to increase the doxorubicin dose to that given as a single agent and also maintain the ifosfamide dose. This is now being tested in a randomized trial to determine whether improved response rates and other indicators of outcome will be seen.
authors.affiliation: University of Birmingham, UK.
authors.forename: G
authors.initials: G
authors.lastname: Blackledge
authors.forename: W P
authors.initials: WP
authors.lastname: Steward
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: H
authors.initials: H
authors.lastname: Mouridsen
authors.forename: V
authors.initials: V
authors.lastname: Bramwell
authors.forename: J
authors.initials: J
authors.lastname: Schütte
authors.forename: A
authors.initials: A
authors.lastname: van Oosterom
authors.forename: P
authors.initials: P
authors.lastname: Dombernowsky
authors.forename: J
authors.initials: J
authors.lastname: Buesa
authors.forename: M
authors.initials: M
authors.lastname: Van Glabekke
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
chemical_list: D007069:Ifosfamide